Article
Public, Environmental & Occupational Health
Shanshan Sun, Qiujing Li, Zhenkun Zhang, Sili Xiong, Yujie Zhang, Qian Liu, Zhe Li, Fujun Yang, Shukun Zhang
Summary: SMARCA2-negative expression is an independent predictor of a poor outcome of NSCLC and a potential target for NSCLC treatment.
ENVIRONMENTAL HEALTH AND PREVENTIVE MEDICINE
(2022)
Article
Cell Biology
Jinfeng Zhang, Siyu Hou, Zilong You, Guozheng Li, Shouping Xu, Xianyong Li, Xianyu Zhang, Bo Lei, Da Pang
Summary: The study analyzed the expression and prognostic values of the ARID family in breast cancer, revealing differences in expression levels and outcomes among different molecular subtypes. Some ARID members were associated with favorable outcomes, while others were associated with worse outcomes.
Review
Biochemistry & Molecular Biology
Yu Zeng, Jiqin Zhang, Jianhe Yue, Guoqiang Han, Weijia Liu, Lin Liu, Xin Lin, Yan Zha, Jian Liu, Ying Tan
Summary: DACT plays a critical role in regulating cell proliferation, development, apoptosis, migration, and differentiation. Recent research indicates that it is essential in tumorigenesis and cancer progression, and has the potential to serve as a tumor biomarker and therapeutic target in cancer diagnosis and treatment.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES
(2022)
Article
Oncology
Katharina Moller, Martina Kluth, Malik Ahmed, Lia Burkhardt, Christina Moller-Koop, Franziska Buscheck, Soren Weidemann, Maria-Christina Tsourlakis, Sarah Minner, Hans Heinzer, Hartwig Huland, Markus Graefen, Guido Sauter, Thorsten Schlomm, David Dum, Ronald Simon
Summary: Deletion of chromosome 5q is common in prostate cancer, with separate deletions at 5q13 and 5q21 leading to aggressive disease. Cancers with co-deletion of 5q13 and 5q21 have worse prognosis compared to those with isolated deletions at either locus. 5q21 deletions are associated with ERG negativity, while 5q13 deletions are not related to ERG status.
INTERNATIONAL JOURNAL OF CANCER
(2021)
Article
Cell Biology
Kuan Hu, Lei Yao, Zhijie Xu, Yuanliang Yan, Juanni Li
Summary: The CBXs family proteins, especially CBX3, play important roles in the prognosis and chemoresistance of ovarian cancer. The CBXs family is primarily involved in mast cell activation and mast cell mediated immunity. High expression of CBX3 in ovarian cancer cells is associated with chemoresistance. The CBXs family has a high genetic alteration rate in ovarian cancer.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2022)
Article
Oncology
Shengbo Li, Xiaofan Yang, Wenqing Li, Zhenbing Chen
Summary: E2F1/2/3/5/8 play important roles in the tumor progression of gastric cancer, serving as potential biomarkers or therapeutic targets.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Zheng Fang, Hong-yu Shen, Qi Xu, Hong-lei Zhou, Lei Li, Si-Yuan Yang, Zhen Zhu, Jin-hai Tang
Summary: Breast cancer patients with high expression of PUS1 have poor prognosis and shorter survival time. Knockdown of PUS1 suppresses the proliferation, colony formation, and invasion abilities of breast cancer cells. PUS1 may serve as a promising biomarker and treatment target for breast cancer.
FRONTIERS IN ONCOLOGY
(2022)
Article
Multidisciplinary Sciences
Mintao Xiao, Chunrong Pang, Shixin Xiang, Yueshui Zhao, Xu Wu, Mingxing Li, Fukuan Du, Yu Chen, Fang Wang, Qinglian Wen, Zhangang Xiao, Zhongming Yang, Jing Shen
Summary: This study investigates the dysregulation, prognostic value, and regulatory network of B7 family members in non-small cell lung cancer (NSCLC). The study finds overall dysregulation of B7 family members in NSCLC and highlights the potential of combination use of tyrosine kinase inhibitors or MEK/ERK inhibitors with B7 member blockade for NSCLC treatment. The major pathway affected by B7 family is the EGFR tyrosine kinase inhibitor resistance and ErbB signaling pathway.
SCIENTIFIC REPORTS
(2023)
Review
Medicine, General & Internal
Huandan Suo, Nan Xiao, Kewei Wang
Summary: Recent studies have found that synaptotagmin family plays important roles in various cancers. Down-regulation of synaptotagmins inhibits cancer cell proliferation, migration, and invasion, but promotes cell apoptosis. Therefore, synaptotagmins may serve as potential prognostic biomarkers for multiple cancers.
FRONTIERS IN MEDICINE
(2022)
Article
Genetics & Heredity
Chenxi Pan, Nan Luo, Kun Guo, Wenbo Wang, Lei Li, Ning Fan, Yu Tian
Summary: The high expression of CBX1, CBX2, CBX3, CBX6, and CBX8 was associated with poor survival rates in hepatocellular carcinoma patients. CBX2 and CBX3 were significantly correlated with poor prognosis for hepatocellular carcinoma patients. CBX3 was strongly correlated with immune cell infiltration and involved in regulation of methylation of Histone H3-K27.
FRONTIERS IN GENETICS
(2022)
Article
Cell Biology
Juanni Li, Zhijie Xu, Lei Zhou, Kuan Hu
Summary: In this study, we comprehensively analyzed the expression, prognostic implications, genetic alterations, immune infiltration, and potential biological functions of CBXs in GBM. We found that CBX3 and CBX8 may serve as useful diagnostic and prognostic biomarkers in GBM. Additionally, CBXs exhibited genetic alterations and were associated with immune cell infiltration. These findings provide new insights into finding potential prognostic markers and therapeutic targets in GBM.
Article
Oncology
Hongkai Zhuang, Bo Chen, Chenwei Tang, Xinming Chen, Wenliang Tan, Lei Yang, Zhiqin Xie, Xiaowu Ma, Qingbin Wang, Chuanzhao Zhang, Changzhen Shang, Yajin Chen
Summary: This study systematically investigated the expression pattern and biological values of LSM family members in HCC and identified LSM family members as novel therapeutic targets in HCC.
FRONTIERS IN ONCOLOGY
(2022)
Article
Pharmacology & Pharmacy
Xiaoqian Yu, Xuejie Yang, Hui Nie, Wenying Jiang, Xiaoyun He, Chunlin Ou
Summary: This study investigated the expression, prognosis, gene alterations, functional enrichment, and immunoregulatory effects of the SSTR family members in colon adenocarcinoma (COAD) using bioinformatics. The results showed that SSTR1-4 were downregulated in COAD, and low SSTR2 expression was associated with poor survival. There was a strong correlation between SSTR expression and immune cell infiltration. SSTR2 was identified as a promising target for COAD immunotherapy.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Medicine, General & Internal
Laura Sophie Tribian, Maximilian Lennartz, Doris Hoeflmayer, Noemi de Wispelaere, Sebastian Dwertmann Rico, Clara von Bargen, Simon Kind, Viktor Reiswich, Florian Viehweger, Florian Lutz, Veit Bertram, Christoph Fraune, Natalia Gorbokon, Soeren Weidemann, Claudia Hube-Magg, Anne Menz, Ria Uhlig, Till Krech, Andrea Hinsch, Eike Burandt, Guido Sauter, Ronald Simon, Martina Kluth, Stefan Steurer, Andreas H. Marx, Patrick Lebok, David Dum, Sarah Minner, Frank Jacobsen, Till S. Clauditz, Christian Bernreuther
Summary: Prostate-specific acid phosphatase (PSAP) is a marker for prostate cancer and its expression is limited in normal tissues but higher in prostate cancers. The expression level of PSAP is associated with clinical characteristics and prognosis of prostate cancer, making it a potential marker for prognostic evaluation.
Article
Cell Biology
Hongxi Chen, Lei Zhou, Juanni Li, Kuan Hu
Summary: This study found abnormal expression of ALKBH members in breast cancer and their association with tumor stage and subclasses. Higher alteration rates of ALKBH family were observed in breast cancer and several cancer-associated signal pathways were related to ALKBH family. Infiltration of immune cells was strongly related to ALKBHs. Furthermore, ALKBH7 was correlated with worse prognosis in breast cancer patients.
Article
Multidisciplinary Sciences
Samer Al-Saad, Elin Richardsen, Thomas K. Kilvaer, Tom Donnem, Sigve Andersen, Mehrdad Khanehkenari, Roy M. Bremnes, Lill-Tove Busund
Article
Multidisciplinary Sciences
Yury Kiselev, Sigve Andersen, Charles Johannessen, Bjorn Fjukstad, Karina Standahl Olsen, Helge Stenvold, Samer Al-Saad, Tom Donnem, Elin Richardsen, Roy M. Bremnes, Lill-Tove Rasmussen Busund
SCIENTIFIC REPORTS
(2018)
Article
Physiology
M. B. Aljabri, N. T. Songstad, T. Lund, M. C. Serrano, T. V. Andreasen, S. Al-Saad, S. Lindal, V. Sitras, G. Acharya, K. Ytrehus
Article
Oncology
Tom Donnem, Kenneth Lonvik, Katrine Eklo, Thomas Berg, Sveinung W. Sorbye, Khalid Al-Shibli, Samer Al-Saad, Sigve Andersen, Helge Stenvold, Roy M. Bremnes, Lill-Tove Busund
Article
Cardiac & Cardiovascular Systems
M. B. Aljabri, T. Lund, A. C. Hoper, T. V. Andreasen, S. Al-Saad, S. Lindal, K. Ytrehus
CARDIOVASCULAR TOXICOLOGY
(2011)
Article
Oncology
Tom Donnem, Sigve Andersen, Samer Al-Saad, Khalid Al-Shibli, Lill-Tove Busund, Roy M. Bremnes
CLINICAL LUNG CANCER
(2011)
Review
Oncology
Roy M. Bremnes, Tom Donnem, Samer Al-Saad, Khalid Al-Shibli, Sigve Andersen, Rafael Sirera, Carlos Camps, Inigo Marinez, Lill-Tove Busund
JOURNAL OF THORACIC ONCOLOGY
(2011)
Article
Medicine, Research & Experimental
Tom Donnem, Katrine Eklo, Thomas Berg, Sveinung W. Sorbye, Kenneth Lonvik, Samer Al-Saad, Khalid Al-Shibli, Sigve Andersen, Helge Stenvold, Roy M. Bremnes, Lill-Tove Busund
JOURNAL OF TRANSLATIONAL MEDICINE
(2011)
Article
Oncology
Sigve Andersen, Marte Eilertsen, Tom Donnem, Khalid Al-Shibli, Samer Al-Saad, Lill-Tove Busund, Roy M. Bremnes
Article
Oncology
Helge Stenvold, Tom Donnem, Sigve Andersen, Samer Al-Saad, Khalid Al-Shibli, Lill-Tove Busund, Roy M. Bremnes
Article
Oncology
Sigurd M. Hald, Roy M. Bremnes, Khalid Al-Shibli, Samer Al-Saad, Sigve Andersen, Helge Stenvold, Lill-Tove Busund, Tom Donnem
Article
Multidisciplinary Sciences
Sigve Andersen, Tom Donnem, Khalid Al-Shibli, Samer Al-Saad, Helge Stenvold, Lill-Tove Busund, Roy M. Bremnes
Article
Multidisciplinary Sciences
Sigve Andersen, Tom Donnem, Helge Stenvold, Samer Al-Saad, Khalid Al-Shibli, Lill-Tove Busund, Roy M. Bremnes
Article
Multidisciplinary Sciences
Tom Donnem, Christopher G. Fenton, Kenneth Lonvik, Thomas Berg, Katrine Eklo, Sigve Andersen, Helge Stenvold, Khalid Al-Shibli, Samer Al-Saad, Roy M. Bremnes, Lill-Tove Busund
Article
Oncology
Sigve Andersen, Tom Donnem, Samer Al-Saad, Khalid Al-Shibli, Helge Stenvold, Lill-Tove Busund, Roy M. Bremnes
ANTICANCER RESEARCH
(2011)